This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.
Acta pharmaceutica Sinica. B, 15(2), 707-721
Citation
Guo, Wei; Wen, Xuejun; Chen, Yuhang; Zhao, Tianzhi; Liu, Jia; Tao, Yucen; Fu, Hao; Wang, Hongjian; Xu, Weizhi; Pang, Yizhen; Zhao, Liang; Huang, Jingxiong; Xu, Pengfei; Guo, Zhide; Miao, Weibing; Zhang, Jingjing; Chen, Xiaoyuan; Chen, Haojun. (2025). Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.. Acta pharmaceutica Sinica. B, 15(2), 707-721. https://doi.org/10.1016/j.apsb.2024.05.022